Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fructosamine”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 307 records · Page 17Linked to original sources
PubMed1997

Serum fructosamine: a reference interval for a heterogeneous canine population.

Eighty-nine healthy dogs (44 males, 45 females) of different breeds, 1-12 years of age, living under varied feeding and environmental conditions, were sampled to evaluate a reference interval for serum fructosamine using a nitroblue tetrazolium photocolorimetric method. The analytical assay was evaluated by calculation of within-run and between-day variations. The results were approximately normally distributed and the calculated reference interval was 192.6-357.4 mumol/L (mean 275.0 mumol/ L, standard deviation 41.2 mumol/L). No significant differences attributable to sex or age were observed. This reference interval is wider than those previously reported in less heterogeneous groups of dogs and in those from other geographical zones. The fructosamine values in serum from 3 diabetic dogs all exceeded the upper limit of the reference interval.

Aging↗
PubMedDate not supplied

[Serum fructosamine in healthy and diabetic children and adolescents].

The determination of fructosamine in serum of healthy newborns, children and adolescents by a new colorimetric method leads to an age-dependent reference range. Correction of the values for total protein yields a median of the results, which is not dependent on age and the upper limit of the reference range is not significantly different from that of healthy adults; this does not hold true for referral to albumin. As the half-life time of glycated serum proteins is shorter (mean 20 days) than that of hemoglobin A1c, fructosamine can provide useful additional informations about the diabetic control of children and adolescents (medium-term record of blood glucose).

Adolescent↗
PubMed1994

Serum fructosamine correlates with gingival index in children with insulin-dependent diabetes mellitus (IDDM).

Fructosamine assay, which is used in diagnosing and monitoring diabetic patients, is compared with the hemoglobin and plasma glucose assays in children and adolescent insulin-dependent diabetes mellitus patients. We demonstrated that the gingival index scores were correlated with fructosamine values in insulin-dependent diabetes mellitus patients but not in non-diabetic controls. We also found that there was no correlation between gingivitis scores and fasting plasma glucose and HbA1c values. Periodontitis was found to be rare in diabetic children and adolescents.

Adolescent↗
PubMed2002

Insulinoma in a normoglycaemic dog with low serum fructosamine.

An insulinoma was diagnosed in an eight-year-old, male golden retriever. Four fasted serum glucose concentrations were within the reference values over a seven-week period. Two serum fructosamine values over the same seven-week period were both low. An exploratory laparotomy and histopathology of an excised pancreatic nodule confirmed the diagnosis of insulinoma. This report demonstrates that a dog with a histologically confirmed insulinoma can have normal fasting serum glucose concentrations on multiple assays. It also demonstrates that fructosamine assays may be helpful in the diagnostic evaluation of normoglycaemic dogs with clinical signs suggestive of insulinoma.

Animals↗
PubMed1998

Diabetes mellitus in dogs: a study of the critical difference for canine serum fructosamine.

The purpose of this study was to calculate the critical difference between two analytical measurements of serum fructosamine concentration in dogs. The critical difference can be used to judge whether the difference between two consecutive analytical results from the same animal is due to natural variation. Blood samples from 15 apparently clinically healthy beagle dogs were collected once a week for six consecutive weeks. The serum fructosamine concentration was measured by the reduction test with nitroblue tetrazolium and the critical difference was calculated from the component of variance for weeks within dogs (sigma2s) and the residual variance (sigma2e). The critical difference between two consecutive analytical results was 33.5 micromol/litre.

Animals↗
PubMed1988

Serum fructosamine does reflect levels of glycated serum albumin in insulin-dependent diabetics.

Fructosamine was measured in the serum of 62 patients with insulin-dependent diabetes (IDD) and 32 non-diabetics and the results compared with glycated albumin levels (GSA) measured using the affinity medium Cibarcron blue F3GA. Good correlations were found both for the IDD patients (r = 0.93) and the combined group of IDD plus non-diabetics (r = 0.95). We conclude, that fructosamine measurements accurately reflect GSA concentrations, and, therefore, provide a practical method for assessing intermediate term glycaemia in IDD.

Adolescent↗
PubMedDate not supplied

Dissociation of serum fructosamine from fasting plasma glucose or hemoglobin A1c in diabetics.

To evaluate serum fructosamine as an indicator for diabetic control, serum fructosamine (FRA), glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) were simultaneously measured in 452 diabetics in stable diabetic control. We divided the measured FRA according to the degree of deviation from the expected FRA into three types, hyper-FRA, normo-FRA and hypo-FRA. In the hypo-FRA to HbA1c group, frequencies of male (70 vs 35, 43%) and of nephropathy (61 vs 30, 18%) were higher and mean total serum protein (6.5 vs 7.4, 7.4 g/dl) and albumin (3.4 vs 4.1, 4.0 g/dl) were lower than those in the other two corresponding groups. Correlation was also poorer in the insulin-treated group than the others. These results probably reflect conditions of diabetic control and complication, and protein metabolism. Similar tendencies were observed in case of FPG. Therefore, the discrepancy of FRA gives a clue to detect poor control and complications of diabetes.

Adult↗
PubMed1994

[Usefulness of hemoglobin A1c and fructosamine for screening of glucose intolerance in community adults].

The usefulness of hemoglobin A1c and fructosamine for screening of glucose intolerance were compared in 383 semi-urban residents ranging from 35 to 88 years of age. Both the sensitivity and specificity of the indices for screening of those with 110 mg/dl and over of fasting blood glucose were examined. The results showed that hemoglobin A1c was better than fructosamine for screening for glucose intolerance.

Adult↗
PubMedDate not supplied

Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid.

OBJECTIVE: To determine the pharmacokinetics, safety, and tolerability of a novel, controlled-release oral formulation of alpha-lipoic acid (LA) and to investigate whether sustaining the concentration of LA in plasma would have a beneficial effect on glycemic control in patients with type 2 diabetes. METHODS: For the pharmacokinetic study, a single, 600-mg dose of either controlled-release LA (CRLA) or quick-release LA (QRLA) was administered orally to 12 normal human subjects. The plasma profile of LA was determined for 24 hours after administration of the dose,and pharmacokinetic analyses were performed. For the safety and tolerability study, 21 patients with type 2 diabetes were given 900 mg of CRLA daily for 6 weeks, followed by 1,200 mg of CRLA daily for an additional 6 weeks. Active treatment was followed by a 3-week washout period. Throughout the study, patients continued to take their prestudy antidiabetic medications, which included metformin (Glucophage), sulfonylureas (Amaryl, glyburide, and Glucotrol), acarbose (Precose), troglitazone (Rezulin), and insulin (either as monotherapy or in combination). CRLA was evaluated for safety and tolerability as well as for effects on glycemic control. RESULTS: The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02). No severe side effects or changes in either liver or kidney function or hematologic profiles were noted after the administration of CRLA. In 15 patients, the mean plasma fructosamine concentration was reduced from 313 to 283 micromol/L(P<0.05) after 12 weeks of treatment with CRLA. CONCLUSION: CRLA increased the plasma concentration of LA over time in healthy subjects, and CRLA was safe, well tolerated, and effective in reducing plasma fructosamine in patients with type 2 diabetes.

Acarbose↗
PubMed2003

[Fructosamine, high density lipoproteins and degree of dyslipidemia in patients with vascular complications of diabetes mellitus type I].

The contents of products from lipid peroxidation (LP) and from fructosamine oxidation, associated with high-density lipoproteins (HDLP), were examined in the blood of patients with diabetes mellitus (DM) of type 1. It was established that, as the vascular complications of DM, type 1, (i.e. micro- and macroangiopathies) aggravated, the HDLP level, modified by LP heptanophil products, was growing up in the blood serum. The content of the above category of HDLP-associated lipoperoxides depended directly on a quantity of HDLP-bound fructosamine, and it reached a maximum value at the most pronounced dislipidemic disorders accompanied by clinical signs of arteriosclerosis (macroangiopathies).

Adolescent↗
PubMed2004

[Comparative analysis of dependence of saliva sorbitol and fructosamine levels on blood glucose level in patients with diabetes].

The possibility of determination of sorbitol and fructosamine in saliva has been studied in healthy volunteers and patients with diabetes. The dependence of these metabolites levels in saliva on blood glucose level was demonstrated. It is concluded that saliva sorbitol and fructosamine levels measurements may be used as diagnostic tests in diabetes and serve as indicators of efficacy of therapy in diabetes.

Adult↗
PubMed1991

Maternal serum fructosamine values after delivery of macrosomic babies and unexplained stillbirths.

Measurement of serum fructosamine and haemoglobin A1 levels and glucose tolerance tests were performed in 75 women in the immediate postpartum period. None had predisposing factors to gestational diabetes. They were divided into three groups: group I consisted of 15 women who delivered an unexplained stillbirth; group II of 30 women who gave birth to babies weighing between 2,500 g and 3,900 g at term; and group III of 30 women who delivered babies weighing greater than or equal to 4,000 g. There was a significant difference in the mean level of serum fructosamine between the unexplained stillbirth and control groups (P less than 0.001). Although the HbA1 values varied in the three groups, there was a significant difference between the unexplained stillbirth group and the macrosomic infant group (P less than 0.05). All patients had normal glucose tolerance tests.

Adult↗
PubMed1991

[Some problems in standardization of fructosamine tests].

The degree of nonenzymatic glycation of serum proteins was estimated in 500 nondiabetic subjects and in 124 Type 2 diabetic out-patients. The values were evaluated in relation to a DMF calibration curve, a secondary glycated protein standard and to serum protein concentrations. Neglecting the evaluation with respect to the protein concentration 0.4% of the samples from nondiabetics and 9% from diabetic patients would have been incorrectly interpreted. The fructosamine values from nondiabetic subjects showed a Gaussian distribution. The use of secondary protein standards is a premise to a widespread application of the fructosamine assay in diabetic care. The calibration of such secondary glycated protein standards results in some problems when using DMF protein mixtures as primary standards, because albumin preparations from the same or different suppliers gave variable standardization curves.

Adult↗
PubMed1990

The fructosamine assay in diagnosis and control of diabetes mellitus scientific evidence for its clinical usefulness?

The fructosamine assay is about to be used for the control of diabetic patients and for the diagnosis of diabetes mellitus. An analysis of the original literature is presented to answer the question whether the evaluation of the test is methodologically reliable. Altogether 65 studies are evaluated. Thirty of these studies deal with technical aspects of the test (phase 1). A comparison of the distributions of test results for diabetic and non-diabetic patients is presented in 28 studies (phase 2). However, serious shortcomings in methodology and presentation are apparent. "Significant" differences and correlation coefficients are the basis for optimistic conclusions. Only 7 studies are identified where fundamental test parameters such as sensitivity and specificity are given, or can be calculated (phase 3). None of them achieves a satisfactory standard of methodology (selection of patients unclear, assessment made not mutually blind). There is no reliable phase-3-study for the metabolic control of diabetes mellitus. It can be concluded that the fructosamine test is not evaluated sufficiently to allow its routine clinical use. In fact, contrary to a widely quoted opinion, the results presented so far do not suggest a reliable test.

Child↗
PubMed1990

[Venous stasis and orthostasis as factors influencing fructosamine concentration].

The concentrations of high molecular weight blood constituents are influenced by the increased intravascular pressure at sample collection. The impact on the fructosamine concentration was compared with that on total protein, plasma protein, electrolytes, and protein bound analytes such as calcium. The results show that fructosamine concentration behaves similar to that of total protein and albumin with change in resting position and venous-stasis.

Adult↗
PubMedDate not supplied

[Control of the metabolic state of diabetic patients by determining the concentration of serum glycosylated proteins (the fructosamine test)].

The method for determining glycosylate serum proteins is based on the ketoamines property (fructosamine) of reducing nitro-tetrazoline blue, in alkaline medium, to a coloured, photometric product. The technique is simple, rapid, reproducible and cheap. The method was used for investigation of 52 diabetics and 17 normal subjects. The normal values were between 1.50-2.70 mmol/l, uncertain between 2.70-3.00 mmol/l, and certainly pathological above 3.00 mmol/l. The level of serum fructosamines shows the glycemia variations for an average period of about two weeks, before determination. It is one of the valuable parameters for detecting and following the patients with diabetes mellitus, and has also a prognostic value in the evolution of the disease.

Adolescent↗
PubMed1989

[2,070 simultaneous determinations of blood glucose, glucosylated hemoglobin and fructosamine as index of metabolic control in 519 diabetic patients].

Two thousand and seventy simultaneous determinations of glucose, glucosylated hemoglobin (HbA1) and plasma fructosamine have been performed in 519 diabetic patients in order to obtain a follow up index and metabolic profile. This retrospective study points out the difficulty of achieving a good metabolic control in diabetic patients. Although the determination of plasma glucosylated proteins (HbA1 and fructosamine) has meant a great improvement in diabetic control, the study of the correlation of the above mentioned.

Adolescent↗